Elan Financial Statements
Elan Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Elan Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 1,000.2 | 759.4 | 560.4 |
| Gross Profit ($ mil.) | 506.8 | 421.5 | 349.2 |
| Operating Income ($ mil.) | (154.1) | (285.0) | (164.8) |
| Total Net Income ($ mil.) | (71.0) | (405.0) | (267.3) |
| Diluted EPS (Net Income) | (0.15) | (0.86) | (0.62) |
Elan Quarterly Statements
| Quarter Ending Sep 09 | Quarter Ending Jun 09 | Quarter Ending Mar 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 287.0 | 280.9 | 245.1 |
| Gross Profit ($ mil.) | 144.9 | 141.5 | 116.3 |
| Operating Income ($ mil.) | 102.8 | (16.5) | (54.8) |
| Total Net Income ($ mil.) | 52.3 | (68.2) | (102.6) |
| Diluted EPS (Net Income) | 0.11 | (0.14) | (0.22) |
Elan Stock Quote & Chart
11/06/09 16:03:37 EST •
NYSE •
6.58
•
 +0.3800
•
+6.1290 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Elan Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 2.76 | 2.28 | 7.00 |
| Price/Earnings Ratio | (34.72) | 27.25 | 25.45 |
| Price/Book Ratio | (7.78) | 3.42 | 6.74 |
| Price/Cash Flow Ratio | (17.18) | 19.72 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Elan Financial Ratios
Elan Competitive Intelligence
| Bayer Schering Pharma | Merck Serono | Pfizer | |
|---|---|---|---|
| Annual Sales ($ mil.) | 46,397.9 | 922.9 | 48,296.0 |
| Employees | -- | 800 | 81,800 |
| Market Cap ($ mil.) | -- | -- | 114,870.4 |
Competitive Landscape
